Payment overview · 2025
General Payments
$340.99
14 reported records · 4 companies
Healthcare provider profile · identity verified
Ashok Bhandari, MD
Allopathic & Osteopathic Physicians|Internal Medicine · KNOXVILLE, TN · NPI 1083671648
Verified facts
What the public records show
CMS Open Payments records show Ashok Bhandari, MD received $340.99 in general payments during 2025 across 14 reported records.
AstraZeneca Pharmaceuticals LP accounted for 67.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Trelegy Ellipta by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $231.55 | 67.9% | 10 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $64.19 | 18.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $25.61 | 7.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.64 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $340.99 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $92.88 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $70.51 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $64.19 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $40.02 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $25.61 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 57 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 112 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
112 | 30 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
57 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 561 | 109 |
| Gabapentin | Gabapentin | 520 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 506 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 378 | 76 |
| Atorvastatin Calcium | Atorvastatin Calcium | 320 | 75 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 283 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 280 | 60 |
| Lisinopril | Lisinopril | 265 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 205 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 198 | 67 |
| Metformin Hcl | Metformin Hcl | 191 | 40 |
| Trazodone Hcl | Trazodone Hcl | 186 | 36 |
| Omeprazole | Omeprazole | 185 | 37 |
| Potassium Chloride | Potassium Chloride | 183 | 45 |
| Losartan Potassium | Losartan Potassium | 179 | 38 |
| Furosemide | Furosemide | 172 | 47 |
| Montelukast Sodium | Montelukast Sodium | 169 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 149 | 35 |
| Mirtazapine | Mirtazapine | 127 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 126 | 25 |
| Jardiance | Empagliflozin | 117 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 112 | 30 |
| Clonidine Hcl | Clonidine Hcl | 110 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 102 | 30 |
| Sertraline Hcl | Sertraline Hcl | 100 | 23 |
| Allopurinol | Allopurinol | 96 | 23 |
| Buspirone Hcl | Buspirone Hcl | 96 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 95 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 15 |
| Bumetanide | Bumetanide | 92 | 20 |
| Eliquis | Apixaban | 88 | 19 |
| Carvedilol | Carvedilol | 86 | 21 |
| Clonazepam | Clonazepam | 86 | 12 |
| Ozempic | Semaglutide | 86 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 83 | 20 |
| Tramadol Hcl | Tramadol Hcl | 81 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 27 |
| Glimepiride | Glimepiride | 76 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 75 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 15 |
| Alprazolam | Alprazolam | 61 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 12 |
| Donepezil Hcl | Donepezil Hcl | 59 | 15 |
| Gemtesa | Vibegron | 57 | 14 |
| Benazepril Hcl | Benazepril Hcl | 56 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 56 | 25 |
| Baclofen | Baclofen | 53 | 20 |
| Meloxicam | Meloxicam | 53 | 25 |
| Ezetimibe | Ezetimibe | 52 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Atenolol | Atenolol | 49 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 48 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 48 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 47 | 15 |
| Meclizine Hcl | Meclizine Hcl | 45 | 17 |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Azithromycin | Azithromycin | 44 | 39 |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 28 |
| Metformin Hcl Er | Metformin Hcl | 42 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 39 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 39 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Famotidine | Famotidine | 37 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 35 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Novolog Flexpen | Insulin Aspart | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Levofloxacin | Levofloxacin | 32 | 23 |
| Pregabalin | Pregabalin | 32 | suppressed |
| Prednisone | Prednisone | 31 | 16 |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 28 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 11 |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Nystatin | Nystatin | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Jantoven | Warfarin Sodium | 17 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Clonidine | Clonidine | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Temazepam | Temazepam | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $340.99 · 14 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, FARXIGA, GEMTESA, GVOKE HYPOPEN, TRELEGY ELLIPTA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error